Residency · Residency · Medical Genetics Genomics
Genetic Testing in Minors: Ethical Frameworks
Introduction
Genetic testing in children and adolescents raises distinct ethical questions that balance the child's current and future interests, parental authority, and the potential for medical benefit. Professional guidelines from the ACMG, AAP, and other organizations provide frameworks for navigating these decisions, but clinical scenarios frequently test the boundaries of established recommendations.
Guiding Ethical Principles
Best Interest of the Child
The primary ethical consideration in pediatric genetic testing is whether testing serves the child's medical interests. Immediate medical benefit through diagnosis, treatment modification, or surveillance initiation strongly supports testing. When no immediate benefit exists, deferral may be appropriate to preserve the child's future autonomy in making their own testing decisions as an adult.
Parental Authority and Its Limits
Parents have broad authority to make medical decisions for their children, rooted in the presumption that parents act in their child's best interest. However, parental authority is not absolute and is limited when decisions could cause net harm to the child. The mature minor doctrine recognizes that older adolescents may have capacity for independent medical decision-making, even when they have not reached the legal age of majority.
The Child's Evolving Autonomy
As children mature, their capacity for understanding and decision-making increases. The concept of assent, which is the child's affirmative agreement to participate, should be sought when developmentally appropriate, typically by age 7-12 years. Adolescents approaching adulthood should be increasingly involved in genetic testing decisions. The right to an open future, meaning the preservation of the child's ability to make autonomous decisions as an adult, is a key ethical consideration particularly relevant to predictive testing for adult-onset conditions.
Categories of Genetic Testing in Minors
Diagnostic Testing
Testing a symptomatic child to establish a genetic diagnosis is generally supported by all professional guidelines regardless of the child's age. Benefits include ending the diagnostic odyssey, guiding treatment, informing prognosis, facilitating family planning for parents, and connecting to condition-specific resources and support networks. Even when no treatment exists, a diagnosis provides tangible benefits to the child and family through prognostic clarity and access to community support.
Predictive Testing for Childhood-Onset Conditions
Testing an asymptomatic child for a condition that may manifest in childhood and for which surveillance or intervention is available in the pediatric age range is generally supported. Examples include testing for familial adenomatous polyposis (APC), retinoblastoma (RB1), multiple endocrine neoplasia type 2 (RET), long QT syndrome, and Li-Fraumeni syndrome. The availability of childhood-onset surveillance or preventive measures justifies presymptomatic testing because the results will directly change clinical management during childhood.
Predictive Testing for Adult-Onset Conditions
Testing an asymptomatic child for a condition that typically manifests in adulthood, such as BRCA1/2-associated cancer risk, Huntington disease, or hereditary hemochromatosis, is generally not recommended in childhood when no medical intervention would be initiated before adulthood. The rationale centers on preserving the child's future autonomous right to decide whether to learn their genetic status, preventing potential psychosocial harm through labeling or altered parental expectations, and avoiding insurance discrimination. Exceptions may arise when there is significant familial anxiety, when the child is a mature adolescent requesting testing, or when the specific condition has childhood-relevant implications that warrant earlier knowledge.
Carrier Testing
Testing a child for carrier status of autosomal recessive or X-linked conditions is generally deferred until the individual can make their own reproductive decisions, as carrier status typically has no health implications for the child. Exceptions exist when carrier status may have health implications, such as sickle cell trait and exercise-related complications, or when balanced chromosomal rearrangements with reproductive implications are considered in mature adolescents approaching reproductive age.
| Testing Category | Example | Recommended Approach | Rationale |
|---|---|---|---|
| Diagnostic (symptomatic child) | Testing a child with developmental delay | Supported at any age | Direct medical benefit; guides management |
| Predictive for childhood-onset condition | APC testing in FAP family; RB1; RET | Supported when surveillance starts in childhood | Medical intervention available before adulthood |
| Predictive for adult-onset condition | BRCA1/2; Huntington disease; APOE | Generally deferred to adulthood | Preserves future autonomy; no childhood intervention |
| Carrier testing (reproductive) | CF carrier; sickle cell trait | Deferred until reproductive decision-making age | No health implications; reproductive relevance only |
| Carrier with health implications | Sickle cell trait (exercise risk); balanced translocation in older adolescent | May be appropriate in adolescence | Direct health or near-term reproductive relevance |
| Secondary findings (pediatric WES/WGS) | BRCA2 found incidentally | ACMG supports returning (controversial) | Enables parental cascade testing; debated for child's autonomy |
Professional Guidelines
ACMG Points to Consider (2015, updated 2021)
The ACMG position supports diagnostic testing in symptomatic children regardless of age and predictive testing for childhood-actionable conditions. Predictive testing for adult-onset conditions should generally be deferred. Carrier testing should generally be deferred until the individual can provide informed consent. Regarding secondary findings, the ACMG recommends returning childhood-actionable ACMG SF variants when exome or genome sequencing is performed in children. Adult-onset findings on the SF list may also be returned to enable parental cascade testing, though this recommendation remains among the more debated aspects of the guidelines.
AAP/ACMG Joint Statement
The joint statement from the American Academy of Pediatrics and ACMG emphasizes the best interest of the child as the primary consideration. It supports diagnostic and predictive testing when medical benefit exists in childhood and recommends genetic counseling for families considering testing. The statement acknowledges that parental request alone is insufficient justification for predictive testing of adult-onset conditions when no childhood benefit exists.
Adolescent-Specific Considerations
Mature minors, typically age 14-17 depending on jurisdiction, may have the capacity to consent to or refuse genetic testing. Assessment of decision-making capacity should be individualized rather than solely age-based. Adolescent assent or dissent should be given significant weight in the clinical decision. Emerging adulthood at ages 16-18 represents an appropriate time to begin discussing predictive testing for adult-onset conditions that will become relevant in the near future.
Challenging Scenarios
Parental Request for Adult-Onset Condition Testing
When parents request BRCA1/2 testing for their 10-year-old daughter after the mother is diagnosed with breast cancer, the recommended approach involves acknowledging parental concern while explaining that testing is deferred because no intervention would change before adulthood. Genetic counseling for the parent should be offered along with a documented plan to discuss testing with the child when she approaches adulthood.
Huntington Disease Predictive Testing
Huntington disease testing in minors is particularly fraught because there is no prevention or treatment. International guidelines from the HDSA and IHA strongly recommend against predictive testing in minors. Testing a child may inadvertently reveal a parent's status if the parent is the at-risk individual who has not been tested. Rare exceptions may be considered for mature adolescents who are requesting testing with appropriate psychological preparation and counseling.
Secondary Findings in Pediatric Exome/Genome Sequencing
When a child undergoing diagnostic exome sequencing is found to carry a pathogenic BRCA2 variant as a secondary finding, the ACMG SF recommendations support returning this finding even in children, primarily to enable parental cascade testing. The child's parents should receive genetic counseling about the implications for both the child's future and the family as a whole. This scenario represents one of the more debated aspects of the ACMG SF recommendations because it conflicts with the general principle of deferring adult-onset condition testing in minors.
Adoption and Foster Care
When genetic testing is requested by adoptive parents or social services for a child with unknown family history, testing should be limited to conditions with immediate clinical relevance. The child's future autonomy regarding genetic information should be protected. Consent authority may be complex depending on custody arrangements.
Psychosocial Considerations
Several psychosocial impacts of genetic testing in minors warrant attention. Labeling occurs when a child identified as carrying a pathogenic variant is treated differently by parents, teachers, or peers. Altered expectations may develop as parents consciously or unconsciously modify their aspirations or parenting approach for a child with a known genetic predisposition. Survivor guilt may affect children who test negative if siblings test positive. Anxiety and distress can develop even when testing identifies a treatable condition, as the knowledge of genetic risk carries its own psychological burden. Research in Huntington disease families shows that predictive testing in minors can have both positive and negative psychosocial effects depending on family context and available support.
Clinical Pearls
Diagnostic testing of symptomatic children is appropriate at any age, and the ethical debate centers specifically on predictive and carrier testing of asymptomatic minors. Predictive testing for adult-onset conditions should generally be deferred to preserve the child's future autonomy, unless childhood-relevant medical interventions exist that would change management. The child's assent should be sought when developmentally appropriate, and the adolescent's dissent should be given significant weight in the decision-making process. Secondary findings from pediatric exome or genome sequencing may include adult-onset conditions; the ACMG supports returning these findings, but this requires careful genetic counseling about implications for both the child and the broader family.
References
- Botkin JR, Belmont JW, Berg JS, et al. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Journal of Human Genetics. 2015;97(1):6-21.
- Committee on Bioethics, Committee on Genetics, American College of Medical Genetics. Ethical and policy issues in genetic testing and screening of children. Pediatrics. 2013;131(3):620-622.
- European Society of Human Genetics. Genetic testing in asymptomatic minors: recommendations of the European Society of Human Genetics. European Journal of Human Genetics. 2009;17(6):720-721.
- Wakefield CE, Hanlon LV, Tucker KM, et al. The psychological impact of genetic information on children: a systematic review. Genetics in Medicine. 2016;18(8):755-762.